Subgroup of colorectal cancer patients ID'd: Do poorly, could benefit from immunotherapy
While the medical community agrees immune cells inside a tumor leads to improved health outcome, for a subset of colorectal cancer patients, having too much of a good thing is a strong predictor of disease recurrence and reduced chances of survival. Scientists identify patients who could benefit from immunotherapy. This is the first report of immune infiltrated tumors with poor health outcomes and is counter to the standard belief in the field.
Read more